Trethera and UCLA Publish Comprehensive Review Highlighting Deoxycytidine Kinase as a Novel Metabolic Target for Cancer Therapy

Trethera and UCLA publish peer-reviewed manuscript highlighting dCK as a novel cancer target and TRE-515 as the first clinically tested dCK inhibitor